Nuclease-based gene editing technology has opened up how biotechs approach genomic research in industry. A review by Boston Consulting Group explores the background to this excitingly complex field, highlighting how the lengthy genetic revolution has been leading up to this point.
Boston Consulting Group has released a report on the importance of gene editing to the biotech industry, and how it is revolutionizing innovation, discovery and creation of new patented tech.
What is meant by Gene Editing?
Engineering controlled gene ‘breakages’ in DNA has led to the development of several major new techniques in homologous recombination of genetic material. Use of nuclease-based gene editing technology (using enzymes which cleave genes at specific target locations) has massively improved the efficiency of gene editing, allowing biotechs to achieve far more research in human therapeutics in a smaller time-frame, and at a reduced cost.
Currently there are 4 major nuclease-based gene editing technologies which exist for research; Meganucleases, Zinc-Finger, Transcription activator-like effector (TALE) and Clustered regularly interspaced short palindromic repeats (CRISPR).